100 episodes

The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research American College of Cardiology

    • Health & Fitness
    • 3.7 • 43 Ratings

The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.

    Ultimate DAPT Trial Principal Results - Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding

    Ultimate DAPT Trial Principal Results - Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding

    Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.
    In this interview, Gregg W Stone MD, FACC and Anthony N. DeMaria MD, MACC discuss principal results from the Ultimate DAPT Trial.
    Subscribe to ACCEL Lite
    Other ACC resources on DAPT and bleeding risk:
    1.      One-Month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes - IVUS-ACS/ULTIMATE-DAPT
    2.      Study Suggests Most Patients with Acute Coronary Syndromes Can Safely Stop Aspirin One Month After Percutaneous Coronary Intervention
    3.      ACC.24 Presentation Slides | ULTIMATE-DAPT

    • 11 min
    Be Active RCT: Gamification & Financial Incentives to Increase Physical Activity

    Be Active RCT: Gamification & Financial Incentives to Increase Physical Activity

    The Be Active trial demonstrates the efficacy of scalable interventions, incorporating remote monitoring and behavioral economics, in boosting physical activity among high-risk cardiovascular patients. Lasting effects were observed even six months post-intervention. While additional data may be warranted for some stakeholders, these interventions hold promise as integral components of exercise-based prevention strategies for cardiovascular disease. 

    In this interview, Alexander Fanaroff, MD, MHS and Glenn A. Hirsch MD, MHS, FACC discuss results from the Be Active RCT. 

     

    Subscribe on Apple Podcasts |  

    • 9 min
    Statin Intolerance, Inclisarin, and the VICTORION-INITIATE Trial

    Statin Intolerance, Inclisarin, and the VICTORION-INITIATE Trial

    The VICTORION-INIATATE study demonstrated that initiating inclisiran, a highly potent lipid-lowering therapy, upon failure to achieve lipid targets with statins, yielded superior outcomes compared to standard care. This approach facilitated a greater proportion of patients in reaching LDL-C targets recommended by current guidelines. Presently, the conventional management of cholesterol disorders in the US routinely falls short of attaining treatment goals for the majority of patients. 

    In this interview, Michael J. Koren, MD, FACC, and C. Noel Bairey Merz, MD, FACC discuss results from the VICTORION-INITIATE randomized trial. 

    • 12 min
    ARISE-HF Primary Results: Selective Aldose Reductase Inhibitor For Diabetic Cardiomyopathy

    ARISE-HF Primary Results: Selective Aldose Reductase Inhibitor For Diabetic Cardiomyopathy

    Heart failure is an increasingly recognized complication in chronic diabetes that may be caused by a number of processes including direct effects of hyperglycemia on the heart muscle. So-called diabetic cardiomyopathy may affect up to 20% of people with chronic diabetes and represents a unique target for treatment. 

     In this interview, James Januzzi, MD, FACC, and Alison L. Bailey, MD FACC discuss the primary results from the ARISE-HF study: Selective Aldose Reductase Inhibitor For Diabetic Cardiomyopathy. 

     Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

    • 11 min
    The Future of Cardiology - Value-Based Care, Private Equity and the Practice Landscape

    The Future of Cardiology - Value-Based Care, Private Equity and the Practice Landscape

    It's becoming increasingly evident that alongside top-notch clinical expertise, the CV specialist of the future must be surrounded by a multi-talented, diverse team to provide optimal patient care. In addition, it is crucial that the clinician and CV organization engage in non-clinical competencies to enhance value for patients, the healthcare system, and society. MedAxiom and ACC collaborate synergistically toward achieving these goals. 

    In this interview, Jerry Blackwell MD, MBA, FACC and Joseph E. Marine MD, MBA, FACC, discuss The Future of Cardiology - Value-Based Care, Private Equity and the Practice Landscape. 

      

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

    • 12 min
    EMPACT-MI Results: Empagliflozin After Acute Myocardial Infarction

    EMPACT-MI Results: Empagliflozin After Acute Myocardial Infarction

    Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart failure continues to be unacceptably high. No intervention in 2 decades has been shown to improve this risk. 

     In this interview, Javed Butler, MD, MPH, MBA, and Sun Moon Kim, MD, FACC, discuss the results of the EMPACT-MI trial. 

    • 11 min

Customer Reviews

3.7 out of 5
43 Ratings

43 Ratings

JMW-WW1 ,

Spotty coverage

Occasionally, the interviewers and their subjects provide important new information or well thought out summaries of new guidelines. More often than not however this feels like a talk show, with some nice discussion and nothing new that I will implement in my practice. Some of the interviewers in particular are extremely flowery and complementary, bordering on obsequious and nauseating.

HearFixr ,

Too LITE

The prior versions when hosted by the late Fred Bovie and Spencer King were more in depth with printed summary and references. Thie current version is lacking in depth of analysis and is fittingly called ACCEL Lite.

this stuff is real ,

ACCEL

I always enjoyed the prior ACCEL recordings that were very informative. The ACCEL lite interviews are interesting but lack the depth of the previous longer interview format.

Top Podcasts In Health & Fitness

On Purpose with Jay Shetty
iHeartPodcasts
Huberman Lab
Scicomm Media
The School of Greatness
Lewis Howes
Uncared For
Lemonada Media
Passion Struck with John R. Miles
John R. Miles
Pursuit of Wellness
Mari Llewellyn

You Might Also Like

Eagle's Eye View: Your Weekly CV Update From ACC.org
American College of Cardiology
JACC Podcast
American College of Cardiology
This Week in Cardiology
Medscape
Cardionerds: A Cardiology Podcast
CardioNerds
ACC CardiaCast
American College of Cardiology
NEJM This Week
NEJM Group